Fundraising Fox

🦊/Companies

Spinogenix

Los Angeles, US · Founded 2016 · Delaware corporation

Find your way into Spinogenix

501 people in our graph share verified history with the Spinogenix team — schools, employers, funds. One of them is your warm intro.

Anthony Linunlockedknows Stella Sarraf · together at University of California, Berkeley (overlapped)

×6knows the team · via University of California, Berkeley

×4knows the team · via Columbia University

knows the team · via Foresite Capital

Spinogenix is a biopharmaceutical company developing therapies to restore synaptic function, with a pipeline aimed at neurological and neurodegenerative conditions.

Biotech Deep Tech Digital Health Healthtech

Founders & leadership

Spinogenix was founded in 2016 by Stella Sarraf, Ph.D. and Stella Sarraf.

SS

Stella Sarraf, Ph.D.Co-founder

SS

Stella Sarraf

Stella Sarraf inCEO, Founder & DirectorStella Sarraf founded Spinogenix to develop therapies restoring synaptic function for neurological and neurodegenerative conditions. She previously founded Amydis in 2013 to develop diagnostic biomarker detection technology, and has spent a decade in venture capital and held roles as a senior research chemist in pharmaceutical companies.

PV

Peter Vanderklish

Peter VanderklishinChief Science Officer

SG

Sharron Gargosky

Sharron Gargosky inChief Development OfficerSharron Gargosky holds a PhD from the University of Adelaide and completed postdoctoral training at Stanford University; she brings 30 years of experience in clinical development and regulatory affairs across pharmaceutical and biologic programs, including FDA approval processes.

RM

Ryan MacDonald

Ryan MacDonaldChief Business Officer

SD

Sasha Damouni Ellis

Sasha Damouni EllisHead of Investor Relations

FH

Franz HeftiNamed on SEC filing

JS

Josh SwartzNamed on SEC filing

Board

SY

Steve YoungBoard director

JL

Jerre L. SteadBoard director

MT

Mervyn Turner, Ph.D.Board director

CE

Craig Erickson

Craig EricksonChief Medical Advisor

Reported raises · per SEC filings

Form D private placements

$24.7M disclosed across 7 rounds · 2017–2025

▶$10.6MraisedMar 2026 · 5 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Steve YoungDirector
Stella Sarraf, Ph.D.Executive Officer, Director
Jerre L. SteadDirector
Mervyn Turner, Ph.D.Director

Offering amount: $35M
Amount sold: $10.6M
First sale: Nov 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$2.8MraisedJun 2024 · 3 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Mervyn TurnerDirector
Dan AlbostaExecutive Officer
Stella SarrafExecutive Officer, Director
Peter Whitney VanderklishExecutive Officer
Jerre SteadDirector

Offering amount: $25M
Amount sold: $2.8M
First sale: Jun 2024
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$5.2MraisedAug 2023 · 3 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Vincent SimmonExecutive Officer, Director
Stella SarrafExecutive Officer, Director
Mervyn TurnerDirector
Peter Whitney VanderklishExecutive Officer

Offering amount: $5.2M
Amount sold: $5.2M
First sale: Jul 2023
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$3.3MraisedSep 2022 · 3 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Stella SarrafExecutive Officer, Director
Peter Whitney VanderklishExecutive Officer
Vincent SimmonExecutive Officer

Offering amount: $3.3M
Amount sold: $3.3M
First sale: Sep 2022
Incorporated: Corporation, De
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$1.6MraisedFeb 2021 · 22 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Stella SarrafExecutive Officer, Director
Franz HeftiDirector
Vincent SimmonExecutive Officer
Peter VanderklishExecutive Officer

Offering amount: $2.3M
Amount sold: $1.6M
First sale: Feb 2021
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$250KraisedSep 2020 · 12 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Stella SarrafExecutive Officer, Director
Vincent SimmonExecutive Officer
Peter Whitney VanderklishExecutive Officer
Franz HeftiDirector

Offering amount: $250K
Amount sold: $250K
First sale: Aug 2019
Incorporated: Corporation, Delaware, 2016
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$903.3KraisedMay 2018 · 10 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Stella SarrafExecutive Officer, Director
Franz HeftiDirector
Josh SwartzDirector

Offering amount: $903.3K
Amount sold: $903.3K
First sale: Sep 2017
Incorporated: Corporation, Delaware, 2016
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap

Bioworld47 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Biogen Idec31 shared keywordsBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.

Companies competing with Spinogenix for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken

Agency	Phase	Year	Amount
National Institutes of Health (NIH)National Institutes of Health	Phase II	2023	$1.4M
National Institutes of Health (NIH)National Institutes of Health	Phase I	2018	$314.5K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Spinogenix has filed a notice of an exempt offering of securities to raise $35 Million in New Funding. - intelligence360intelligence360.news · Mar 2026

Spinogenix Announces FRAXA Research Foundation Support for PIs Leading Phase 2b Trial of Investigational Therapy SPG601 for People with Fragile X Syndrome (FXS) - Spinogenixspinogenix.com · Mar 2026

Frequently asked questions

What does Spinogenix do?: Spinogenix is a biopharmaceutical company developing therapies to restore synaptic function, with a pipeline aimed at neurological and neurodegenerative conditions.
Who founded Spinogenix?: Spinogenix was founded by Stella Sarraf, Ph.D., Stella Sarraf in 2016.
How much funding has Spinogenix raised?: Spinogenix has disclosed $24.7M raised across 7 rounds.
Where is Spinogenix headquartered?: Spinogenix is headquartered in Los Angeles, US.